Ludwig Kappos Selected Research

Multiple Sclerosis

10/2022	Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
10/2022	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
4/2022	Multiple Sclerosis Relapses Following Cessation of Fingolimod.
1/2022	Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
1/2022	A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis.
1/2022	Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
1/2022	Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
1/2022	Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
1/2022	Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
1/2022	Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ludwig Kappos Research Topics

Disease

187	Multiple Sclerosis 10/2022 - 01/2003
72	Relapsing-Remitting Multiple Sclerosis 01/2022 - 05/2003
18	Chronic Progressive Multiple Sclerosis 09/2022 - 12/2010
16	Infections 12/2020 - 02/2010
14	Disease Progression 01/2022 - 06/2004
11	Atrophy 01/2022 - 12/2010
10	Progressive Multifocal Leukoencephalopathy 01/2021 - 01/2008
9	Bradycardia 10/2018 - 02/2010
7	Atrioventricular Block 11/2019 - 02/2010
6	Inflammation (Inflammations) 01/2022 - 02/2007
5	Lymphopenia (Lymphocytopenia) 01/2022 - 06/2014
5	Fatigue 01/2021 - 03/2006
5	Human Influenza (Influenza) 01/2019 - 02/2011
4	Herpes Zoster 01/2018 - 02/2010
4	Hypertension (High Blood Pressure) 01/2018 - 02/2010
4	Stroke (Strokes) 10/2017 - 09/2004
4	Neoplasms (Cancer) 01/2017 - 06/2014
4	Headache (Headaches) 10/2016 - 10/2008
3	Abdominal Pain (Pain, Abdominal) 12/2021 - 10/2008
3	Respiratory Tract Infections (Respiratory Tract Infection) 12/2021 - 10/2014
3	Macular Edema 06/2021 - 02/2010
3	Flushing 05/2019 - 10/2008
3	Diarrhea 01/2016 - 10/2011
3	Nausea 01/2016 - 10/2011
2	Rett Syndrome (Rett's Disorder) 03/2022 - 01/2021
2	Nasopharyngitis 12/2021 - 10/2016
2	Neuromyelitis Optica (Devic's Disease) 01/2021 - 03/2015
2	Opportunistic Infections (Opportunistic Infection) 11/2019 - 05/2007
2	Exanthema (Rash) 05/2019 - 10/2015
2	Chickenpox 01/2018 - 02/2010
2	Basal Cell Carcinoma (Rodent Ulcer) 03/2016 - 06/2014
2	Demyelinating Diseases (Demyelinating Disease) 03/2015 - 12/2011
2	Spinal Cord Injuries (Spinal Cord Injury) 03/2015 - 09/2004
2	Hypersensitivity (Allergy) 07/2014 - 03/2006
2	Injection Site Reaction 05/2014 - 10/2009

Drug/Important Bio-Agent (IBA)

45	Fingolimod Hydrochloride (FTY720)FDA Link 04/2022 - 09/2006
31	Natalizumab (Tysabri)FDA Link 01/2022 - 03/2006
28	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2010
25	teriflunomideIBA 10/2022 - 10/2011
24	Dimethyl FumarateIBA 01/2022 - 10/2008
22	InterferonsIBA 02/2021 - 05/2003
18	Interferon beta-1a FDA Link 01/2022 - 10/2007
15	ocrelizumabIBA 01/2022 - 11/2011
15	Interferon beta-1b (Betaseron)FDA Link 01/2020 - 08/2007
12	Interferon-betaIBA 01/2021 - 02/2004
12	AntibodiesIBA 01/2020 - 01/2007
11	siponimodIBA 09/2022 - 08/2013
11	GadoliniumIBA 01/2022 - 11/2012
9	Immunoglobulin G (IgG)IBA 01/2021 - 01/2007
8	ozanimodIBA 10/2022 - 01/2019
8	Monoclonal AntibodiesIBA 01/2022 - 01/2008
8	EnzymesIBA 12/2021 - 02/2010
7	Sphingosine-1-Phosphate ReceptorsIBA 09/2022 - 05/2014
7	Pharmaceutical PreparationsIBA 01/2021 - 01/2008
7	Immunologic Factors (Immunomodulators)IBA 01/2020 - 02/2012
5	Glatiramer Acetate (Copaxone)FDA Link 01/2021 - 11/2006
5	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 02/2011
5	Daclizumab (Zenapax)FDA Link 01/2021 - 09/2016
5	AntigensIBA 01/2019 - 02/2011
5	Myelin-Oligodendrocyte GlycoproteinIBA 01/2019 - 01/2007
5	Transaminases (Aminotransferases)IBA 01/2018 - 09/2012
5	Neutralizing AntibodiesIBA 06/2012 - 02/2004
4	Immunoglobulin M (IgM)IBA 01/2022 - 01/2007
4	laquinimodIBA 01/2020 - 03/2012
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 06/2015
4	Alanine Transaminase (SGPT)IBA 01/2016 - 03/2014
4	Therapeutic UsesIBA 08/2013 - 02/2004
3	Cytidine Diphosphate (CDP)IBA 01/2022 - 01/2018
3	Alemtuzumab (Campath)FDA Link 01/2022 - 11/2012
3	ofatumumab FDA Link 01/2022 - 01/2020
3	Complement System Proteins (Complement)IBA 01/2021 - 01/2011
3	Vitamin D FDA LinkGeneric 01/2020 - 03/2014
3	hydroxide ionIBA 01/2019 - 08/2014
3	MicroRNAs (MicroRNA)IBA 06/2016 - 07/2012
3	temelimabIBA 10/2015 - 06/2015
3	Influenza Vaccines (Influenza Vaccine)FDA Link 03/2015 - 02/2011
3	Neuroprotective AgentsIBA 03/2015 - 09/2004
3	ImmunosorbentsIBA 10/2013 - 01/2013
2	Rituximab (Mabthera)FDA Link 01/2022 - 01/2019
2	IronIBA 01/2022 - 11/2014
2	Cladribine FDA LinkGeneric 01/2022 - 01/2020
2	VaccinesIBA 11/2021 - 10/2014
2	Biological ProductsIBA 01/2021 - 05/2007
2	Minocycline (Cyclops)FDA LinkGeneric 01/2020 - 03/2015
2	CytokinesIBA 01/2020 - 12/2007
2	Matrix Metalloproteinases (MMPs)IBA 01/2020 - 02/2004
2	Hemagglutinins (Hemagglutinin)IBA 01/2019 - 01/2017
2	amiselimodIBA 10/2018 - 10/2016
2	Oligoclonal BandsIBA 01/2018 - 04/2015
2	AutoantibodiesIBA 01/2017 - 02/2012
2	frovatriptan (Allegro)FDA Link 01/2017 - 08/2014
2	Messenger RNA (mRNA)IBA 06/2016 - 05/2007
2	25-hydroxyvitamin DIBA 12/2015 - 08/2014
2	SteroidsIBA 11/2015 - 03/2014
2	Indicators and Reagents (Reagents)IBA 12/2014 - 08/2013
2	FumaratesIBA 02/2014 - 10/2008

Therapy/Procedure

46	Therapeutics 01/2022 - 02/2004
5	Immunomodulation 10/2019 - 06/2004
3	Cognitive Training 01/2015 - 06/2006
2	Precision Medicine 11/2021 - 09/2021